10-Q quarterly report · filed Nov 5, 2026

Eton Pharmaceuticals, Inc. (ETON) Q3 2026 10-Q Quarterly Report

Short answer

Eton Pharmaceuticals, Inc. (ETON) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $58M (up 157.9% year over year) with net income of $35M.

Q3 2026 key financials · XBRL

Revenue
$58M
+157.9% YoY · +54.1% QoQ
Net income
$35M
+1929.2% YoY · +204.4% QoQ
Operating margin
39.7%
Gross margin
76.5%
EPS (diluted)
$1.07
+1437.5% YoY · +197.2% QoQ

Source: XBRL data from the Eton Pharmaceuticals, Inc. (ETON) Q3 2026 10-Q on SEC EDGAR. USD.

Eton Pharmaceuticals, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $57,925, up $35,466 YoY from $22,459, driven by HEMANGEOL® acquisition and higher product sales
  • Gross margin 76.5% vs 35.0% YoY, gross profit $44,301 vs $7,855
  • Strongest products: ALKINDI SPRINKLE®, KHINDIVI™, INCRELEX® U.S., GALZIN®, DESMODA™, Carglumic Acid; weakest, INCRELEX® outside U.S.
  • Cash $55.6M, operating cash flow $49,901, investing use $18,308 including $14,100 HEMANGEOL® rights payment
  • Near-term headwinds: higher G&A, FDA fees after orphan drug exemption loss, and increased R&D investment in ASN-001 and glyburide oral suspension

Risk Factors

  • No material changes identified from the 2025 10-K risk factors
  • Carried-forward business risk: Unanticipated risks may materially affect operations and financial condition
  • Carried-forward regulatory risk: Additional unknown risks may materially harm future results

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Eton Pharmaceuticals, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.